Literature DB >> 17189108

Incidence, risk factors, and complications of cholelithiasis in patients with home parenteral nutrition.

Xavier Dray1, Francisca Joly, Didier Reijasse, Alain Attar, Arnaud Alves, Yves Panis, Patrice Valleur, Bernard Messing.   

Abstract

BACKGROUND: Previous studies showed high prevalence rates of cholelithiasis in patients with home parenteral nutrition (HPN). Our aim was to determine, in an HPN population, the incidence and risk factors for gallstones and sludge and their complications. STUDY
DESIGN: Retrospective chart review was conducted in a tertiary care center. One hundred fifty-three consecutive patients who received HPN for longer than 2 months (range 2 to 204 months; median 15 months) between 1985 and 1997 were followed with ultrasonography. Kaplan-Meier curves and log-rank tests were calculated to assess risk factors for gallbladder lithiasis and complications.
RESULTS: Thirty-four patients (22%) underwent cholecystectomy before HPN. Of the 119 remaining patients with gallbladder in situ, cholelithiasis appeared during HPN in 45 (38%). The probability of cholelithiasis developing during HPN was estimated to be 6.2%, 21.2%, and 38.7% at 6, 12, and 24 months, respectively. Biliary complications developed in eight patients (7%) during followup. Therapy consisted of endoscopic sphincterotomy (three patients) or operation (five patients) with uncomplicated outcomes except for one patient; no death was observed. Incidence rates of biliary complication during HPN were estimated to be 0.0%, 4.7%, and 10.1% at 6, 12, and 24 months, respectively. Nil or negligible ingesta was the only factor notably associated with incidence of cholelithiasis (p < 0.01) or biliary complications (p < 0.01).
CONCLUSIONS: This first incidence study shows a high rate of cholelithiasis and a low rate of complications during HPN. Both events were notably related to nil or negligible ingesta.

Entities:  

Mesh:

Year:  2006        PMID: 17189108     DOI: 10.1016/j.jamcollsurg.2006.09.008

Source DB:  PubMed          Journal:  J Am Coll Surg        ISSN: 1072-7515            Impact factor:   6.113


  9 in total

1.  Cholecystectomy and Liver Disease in Short Bowel Syndrome.

Authors:  Jon S Thompson; Rebecca A Weseman; Fedja A Rochling; Elizabeth Lyden; Wendy J Grant; Luciano M Vargas; Alan N Langnas; David F Mercer
Journal:  J Gastrointest Surg       Date:  2015-10-26       Impact factor: 3.452

2.  Interstitial Cajal-like cells in human gallbladder.

Authors:  Mihail E Hinescu; Carmen Ardeleanu; Mihaela Gherghiceanu; Laurentziu M Popescu
Journal:  J Mol Histol       Date:  2007-05-31       Impact factor: 2.611

Review 3.  Parenteral Nutrition and Intestinal Failure.

Authors:  Barbara Bielawska; Johane P Allard
Journal:  Nutrients       Date:  2017-05-06       Impact factor: 5.717

4.  Cholelithiasis and Related Morbidity in Chronic Intestinal Failure: a Longitudinal Cohort Study from a National Specialized Centre.

Authors:  Nathan D Appleton; Simon Lal; Gordon L Carlson; Simon Shaw; Philip Stevens; Ioannis Peristerakis; Mattias Soop
Journal:  J Gastrointest Surg       Date:  2018-10-15       Impact factor: 3.452

5.  Prevalence, Risk Factors, and Complications of Cholelithiasis in Adults With Short Bowel Syndrome: A Longitudinal Cohort Study.

Authors:  Xuejin Gao; Li Zhang; Siwen Wang; Yaqin Xiao; Deshuai Song; Da Zhou; Xinying Wang
Journal:  Front Nutr       Date:  2021-11-29

Review 6.  Liver disease secondary to intestinal failure.

Authors:  Bassam Abu-Wasel; Michele Molinari
Journal:  Biomed Res Int       Date:  2014-01-15       Impact factor: 3.411

Review 7.  Gallstones.

Authors:  Gabriel E Njeze
Journal:  Niger J Surg       Date:  2013-07

8.  Frequency of symptoms associated with gallstone disease: a hospital-based cross sectional study.

Authors:  Leila Kanafi Vahed; Leila Khedmat
Journal:  Eur J Transl Myol       Date:  2018-04-24

Review 9.  Intravenous Lipid Emulsions in the Prevention and Treatment of Liver Disease in Intestinal Failure.

Authors:  Fedja A Rochling
Journal:  Nutrients       Date:  2021-03-10       Impact factor: 5.717

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.